Snake venom enzyme nerve growth factor for treating diabetic concurrent peripheral nervous pathological complication

A technology for peripheral neuropathy and nerve growth factor, applied in the direction of nerve growth factor, growth factor/inducer, nervous system diseases, etc., can solve the problem of subjective symptoms not being eliminated

Inactive Publication Date: 2004-01-28
郝文学
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After diabetic patients are treated with traditional Chinese medicine, although the control of blood sugar and urine sugar is relatively satisfactory, the subjective symptoms have not been eliminated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0017] Embodiment preparation process is:

[0018] All operations were performed below 10°C.

[0019] ① CM-Sephadex C50 chromatography

[0020] Take 10g of cobra venom, dissolve it in 100ml of 0.01M sodium acetate buffer solution, pH5.8, after dissolving, centrifuge at 10000 rpm for 10 minutes, take the supernatant, dialyze against 5000ml of the above buffer solution, change the buffer solution 3 times, and then put the sample on The sample was equilibrated with 0.01M acetate buffer solution in a 5.5×100cm chromatographic column, eluted with a linear gradient of 0-0.7M NaCL, and the protein peak with nerve growth factor activity was collected, concentrated and freeze-dried.

[0021] ③ CM-Spharose FF chromatography

[0022] The above-mentioned concentrated sample was dissolved in 20ml of 0.01M sodium acetate buffer solution, pH5.8, and loaded on a chromatographic column 2.6×50cm equilibrated with 0.01M sodium acetate buffer solution pH5.8, linearized with 0-1M NaCl Gradient ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention uses cobra venom as base material for separating and purifying nerve growth factor, and adopts three-step chromatographic separation method to purify unique component nerve growth factor. Said invention can utilize said biologica active substance to improve glycometabolism in the nerve tissue, can promote enlargement of neuron, make the axon grow from proximate to distal endand can increase the number of organella to improve nerve cell function and can improve microcirculation. Said snake venom enzyme nerve growth factor contains arginine lipase, hydrolyzing proteinase and phosphodiesterase, etc. so that it can inhibit platelet aggregation, and can improve blood viscosity and has the functions of thrombolytic agent and vasodilator.

Description

(1) Technical field: [0001] The invention relates to a medicine for treating complications of diabetes mellitus complicated with peripheral neuropathy, in particular to a medicine prepared by extracting biologically active substances. (two) background technology: [0002] Diabetes mellitus is a systemic endocrine and metabolic disease characterized by elevated blood sugar due to the disorder of glucose metabolism in the body. Diabetes develops to a certain extent, especially when combined with chronic vascular and neuropathy, or long-term use of insulin therapy is often accompanied by blood stasis, such as ecchymosis on the face, dark face, limb pain, numbness, fixed pain, Pain in the front of the heart, ecchymosis or petechiae on the side of the tongue, etc. Western medicine often uses sulfonylureas, biguanides and insulin drugs to treat diabetes. Although they have obvious hypoglycemic effects, they can only reach the level of regulating metabolic disorders. Moreover, wes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P3/10A61P25/00C07K14/48
Inventor 郝文学
Owner 郝文学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products